Brief: HBM Holdings Gets IRB Approval For Commencement Of Phase I Trial Of B7h4x4-1Bb Bispecific Antibody In Australia
28/02/2022 02:10
Feb 28 (Reuters) - Hbm Holdings Ltd 2142.HK :
* IRB APPROVAL FOR COMMENCEMENT OF PHASE I TRIAL OF
B7H4X4-1BB
BISPECIFIC ANTIBODY IN AUSTRALIA
Source text for Eikon: ID:nHKS9gT5jn
Further company coverage: 2142.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HBM Holdings
See all newsBrief: HBM Holdings Says NMPA Approves Batoclimab Injection For Generalized Myasthenia Gravis
HBM climbs on development of AI biology foundation model
Brief: HBM Holdings' Unit Develops World's First Language Model For Fully Human Heavy-Chain-Only Antibodies
Brief: Hbm Holdings Says Solstice Oncology Launches Series A Financing Round
HK-listed HBM climbs on initiating next phase of asthma drug study